Spots Global Cancer Trial Database for urothelial cancer
Every month we try and update this database with for urothelial cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | NCT04223856 | Urothelial Canc... | Enfortumab vedo... Pembrolizumab Cisplatin Carboplatin Gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | NCT05219435 | Urothelial Canc... | Nivolumab Ipilimumab | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | NCT03474107 | Ureteral Cancer Urothelial Canc... Bladder Cancer | Enfortumab Vedo... Docetaxel Vinflunine Paclitaxel | 18 Years - | Astellas Pharma Inc | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | NCT03989362 | Cancer | Vopratelimab Ipilimumab | 18 Years - | Jounce Therapeutics, Inc. | |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | NCT04501094 | Urothelial Canc... | Bintrafusp alfa... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | NCT02581982 | Transitional Ce... | Laboratory Biom... Paclitaxel Pembrolizumab | 18 Years - | Wake Forest University Health Sciences | |
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | NCT02891161 | Urothelial Canc... | durvalumab Radiation Thera... | 18 Years - | Big Ten Cancer Research Consortium | |
| Study of INCB086550 in Select Solid Tumors | NCT04629339 | Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma | INCB086550 | 18 Years - | Incyte Corporation | |
| Study of INCB086550 in Select Solid Tumors | NCT04629339 | Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma | INCB086550 | 18 Years - | Incyte Corporation | |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | NCT01331824 | Bladder Cancer | Amrubicin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations | NCT03955913 | Urothelial Canc... Receptors, Fibr... | Archival Tumor ... | 18 Years - | Janssen Research & Development, LLC | |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05267626 | Advanced Solid ... Metastatic Canc... | AU-007 Aldesleukin | 18 Years - | Aulos Bioscience, Inc. | |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study | NCT04712201 | Urothelial Carc... Bladder Cancer | En bloc transur... Conventional TU... | 18 Years - | Fundacio Puigvert | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors | NCT05279690 | Urothelial Canc... Metastatic Soli... | Colchicine | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | NCT02769962 | Urothelial Carc... Urothelial Canc... Lung Neoplasms Small Cell Lung... Prostate Cancer | EP0057 olaparib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | NCT01437488 | Urothelial Carc... | Cabazitaxel Neulasta CT Scan Blood Draw | 18 Years - | Thomas Jefferson University | |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | Advanced and Me... | futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | NCT03179943 | Urothelial Carc... | Atezolizumab Guadecitabine | 18 Years - | Fox Chase Cancer Center | |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | NCT04044859 | Endometrial Can... Esophageal Canc... Esophagogastric... Gastric (Stomac... Head and Neck C... Melanoma Ovarian Cancer Non-small Cell ... Urothelial Canc... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | NCT03207867 | NSCLC, Non Smal... RCC, Renal Cell... Pancreatic Canc... Urothelial Canc... Head and Neck C... DLBCL, Diffused... MSS, Microsatel... TNBC, Triple Ne... Melanoma mCRPC, Metastat... | NIR178 PDR001 | 18 Years - | Novartis | |
| Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | NCT01907308 | Urothelial Carc... | AMG 386 Docetaxel | 18 Years - | University of Colorado, Denver | |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study | NCT04712201 | Urothelial Carc... Bladder Cancer | En bloc transur... Conventional TU... | 18 Years - | Fundacio Puigvert | |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | NCT01700010 | Urothelial Canc... Bladder Cancer | Lapatinib and P... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | NCT03679767 | Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | NCT03387761 | Urothelial Carc... | Ipilimumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| Study of INCB086550 in Select Solid Tumors | NCT04629339 | Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma | INCB086550 | 18 Years - | Incyte Corporation | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract | NCT03474926 | Lymph Node Diss... | Routine Templat... LND only for ly... | 15 Years - 80 Years | RenJi Hospital | |
| Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | NCT04152018 | Squamous Cell C... Renal Cell Carc... Ovarian Cancer Gastric Cancer Esophageal Canc... Lung Squamous C... Pancreatic Canc... Bile Duct Cance... Endometrial Can... Melanoma Cancer Urothelial Canc... | PF-06940434 PF-06801591 | 18 Years - | Pfizer | |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma | NCT02699606 | Neoplasm | Erdafitinib | 18 Years - | Janssen Research & Development, LLC | |
| Description of the Population With Genitourinary Tumors and COVID-19 | NCT04578132 | Covid19 Genito Urinary ... | 18 Years - | Spanish Oncology Genito-Urinary Group | ||
| Sacituzumab Govitecan Plus EV in Metastatic UC | NCT04724018 | Urothelial Canc... Metastatic Urot... Metastatic Urot... Bladder Cancer | Sacituzumab Gov... Enfortumab vedo... | 18 Years - | Dana-Farber Cancer Institute | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer | NCT01206426 | Urothelial Canc... | 18 Years - 89 Years | University of Chicago | ||
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05259397 | Bladder Cancer | PF-07225570 sasanlimab | 18 Years - | Pfizer | |
| Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | NCT03036098 | Urothelial Canc... | Nivolumab Ipilimumab Gemcitabine Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Gemzar, Cisp, Sunitinib Urothelial Ca | NCT00821327 | Urothelial Canc... | Gemcitabine, Ci... | 18 Years - | US Oncology Research | |
| An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | NCT02365597 | Urothelial Canc... | Erdafitinib Midazolam Metformin | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | NCT03914794 | Bladder Cancer NMIBC Non-Muscle Inva... Urothelial Carc... | Pemigatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue | NCT02379429 | Bladder Cancer Urinary Tract C... Urothelial Canc... Healthy Volunte... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | NCT00995488 | Urothelial Canc... Bladder Cancer | ABI-007 (Abraxa... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) | NCT03425201 | Urothelial Canc... | Niraparib plus ... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | NCT00661609 | Bladder Cancer Transitional Ce... Urethra Cancer Ureter Cancer Renal Pelvis Ca... | AZD4877 | 18 Years - | AstraZeneca | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | NCT02256436 | Urothelial Canc... | pembrolizumab paclitaxel vinflunine docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations | NCT03955913 | Urothelial Canc... Receptors, Fibr... | Archival Tumor ... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | NCT04460456 | HER2 Positive S... | SBT6050 pembrolizumab Cemiplimab | 18 Years - | Silverback Therapeutics | |
| Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | NCT05894447 | Urothelial Carc... | Naptumomab Esta... Pembrolizumab Obinutuzumab | 18 Years - | Weill Medical College of Cornell University | |
| Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer | NCT01206426 | Urothelial Canc... | 18 Years - 89 Years | University of Chicago | ||
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | NCT05645692 | Urothelial Canc... | Atezolizumab Tobemstomig Tiragolumab | 18 Years - | Hoffmann-La Roche | |
| Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) | NCT03425201 | Urothelial Canc... | Niraparib plus ... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | NCT01663285 | Urothelial Canc... Bladder Cancer | Neoadjuvant Cis... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | NCT02661100 | Non Small Cell ... Advanced Triple... Small Cell Lung... Urothelial Canc... Mesothelioma Malignant Melan... | Pembrolizumab CDX-1401 Poly-ICLC | 18 Years - | Case Comprehensive Cancer Center | |
| Phase II Study of TKI258 in Advanced Urothelial Carcinoma | NCT00790426 | Urothelial Canc... | TKI258 | 18 Years - | Novartis | |
| HER2 and LA/mUC: A Multi-country Chart Review Cohort Study | NCT05902494 | Urothelial Carc... | 18 Years - | Seagen Inc. | ||
| Pazopanib and Vinflunine in Urothelial Cancer of the Bladder | NCT01265940 | Advanced Urothe... | Pazopanib as ad... | 18 Years - | Lukas-Krankenhaus GmbH | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection | NCT06011954 | Urothelial Canc... | Enfortumab Vedo... | - | Astellas Pharma Inc | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | NCT02256436 | Urothelial Canc... | pembrolizumab paclitaxel vinflunine docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy | NCT05366725 | Urothelial Canc... | Avelumab | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | NCT03472560 | Non-Small Cell ... Urothelial Canc... | Avelumab (MSB00... Axitinib (AG-01... | 18 Years - | Pfizer | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
